Novamind Hosts Clinical Trial to Advance Ketamine Therapy for End-of-Life Patients

TORONTO, ON/ACCESSWIRE/February 3, 2022/ Novamind Inc. (CSE:NM | OTCQB:NVMDF | FSE:HN2) (“Novamind” or the “Company”), a leading mental health company specializing in psychedelic medicine, today announced that it has been selected by the Ketamine Research Foundation (KRF ) to host a Phase II clinical trial of ketamine-assisted psychotherapy (KAP) for adults with life-threatening illness (the “Conscious Death/Life Trial”). conscious”).

The FDA approval of the study’s KAP protocol marks a first in the investigation of KAP for end-of-life patients and its potential to serve as a model of care for this difficult-to-treat population. The mental health toll of terminal illness is well documented; between 24% and 70% of patients suffer from depression with significant negative impacts on quality of life.1 For patients with reduced life expectancies, ketamine may reduce symptoms of depression, anxiety, and existential distress, and improve quality of life. Over the course of six weeks, study participants will undergo two CAP sessions at Novamind’s research site in Murray, Utah, under the supervision of clinical experts.

“This study is an important addition to the clinical care and research opportunities for patients within the psychedelic palliative care program we are building at Novamind,” said Dr. Paul Thielking, Scientific Director and Principal Investigator at the research site. Murray from Novamind. “I have worked with this population for most of my career and, unfortunately, at times felt limited in what I could offer my patients to relieve their emotional distress. The results will contribute to the evidence for the use of KAP with patients with life-threatening disease and provide new insights into alternative treatments.

The Conscious Dying/Conscious Living Trial is sponsored by KRF, a nonprofit leader in ketamine research, advocacy, and clinical education. Phil Wolfson, MD is the founder and CEO of KRF and a pioneer KAP practitioner and instructor. He is also a principal investigator for the Multidisciplinary Association for Psychedelic Studies (MAPS) sponsored Phase II study of MDMA-assisted psychotherapy for people with significant anxiety due to life-threatening illnesses.

Dr Wolfson commented: “Ketamine is still considered a new treatment option for psychiatric illnesses and can sometimes be seen as controversial. Now, with FDA approval, we hope this groundbreaking study will demonstrate KAP’s potential to relieve distress and serve as a model for palliative care practitioners, hospices, and mental health professionals engaged with those who are confronted with death, to help them in their attitudes and choices for the time they have left.

To learn more about the Conscious Dying/Conscious Living trial, please visit this link.

About Novamind
Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics and clinical research sites. Novamind offers ketamine-assisted psychotherapy and other innovative treatments through its network of integrative mental health clinics and operates a full-service contract research organization specializing in clinical trials and evidence-based research for psychedelic medicine. For more information on how Novamind improves mental well-being and guides people through their healing journey, visit

Contact details
Yaron Conforti, CEO and Administrator
Telephone: +1 (647) 953 9512

Samantha DeLenardo, Vice President, Communications
Email: media[email protected]

Investor Relations
E-mail: [email protected]

Forward-looking statements
This press release contains forward-looking statements. All statements other than statements of historical fact included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations, including the risks detailed from time to time in the Company’s public information. Readers are cautioned not to place undue reliance on forward-looking information. The forward-looking statements contained in this press release are expressly qualified by this cautionary statement. The forward-looking statements contained in this press release are made as of the date of this press release and the Company will publicly update or revise any of the forward-looking statements included as expressly required by applicable law.

1: J Palliat Med. 2021 May;24(5):767-781. doi: 10.1089/jpm.2020.0659. Published online March 15, 2021.

THE SOURCE: Novamind Inc.

See the source version on

Comments are closed.